160132-53-6 Usage
General Description
Tert-butyl 3-(2-((methylsulfonyl)oxy)ethyl)pyrrolidine-1-carboxylate is a chemical compound with the molecular formula C14H27NO5S. It is a pyrrolidine derivative with a tert-butyl group at the 3-position and a methylsulfonyl group at the 2-position of the pyrrolidine ring. tert-butyl 3-(2-((Methylsulfonyl)oxy)ethyl)pyrrolidine-1-carboxylate is commonly used in organic synthesis and pharmaceutical research due to its potential therapeutic applications. It has been studied for its anti-inflammatory and analgesic properties, and it may have potential use in the development of new drugs for the treatment of various medical conditions. However, further research is needed to fully understand its biological activity and potential medicinal uses.
Check Digit Verification of cas no
The CAS Registry Mumber 160132-53-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,1,3 and 2 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 160132-53:
(8*1)+(7*6)+(6*0)+(5*1)+(4*3)+(3*2)+(2*5)+(1*3)=86
86 % 10 = 6
So 160132-53-6 is a valid CAS Registry Number.
160132-53-6Relevant articles and documents
AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF
-
, (2018/12/02)
The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.
Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
-
, (2008/06/13)
The invention relates to cyclic urea derivatives of general formula I STR1 wherein Ra, Rb, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation inhibiting effects, and to drugs containing the compounds and processes for preparing them.